Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression. Ghanta P, Verma AK, Lin CH, Charan M, et al. Breast Cancer Res 2026;28:112.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ghanta P, Verma AK, Lin CH, Charan M, et al. Therapeutic targeting of RAGE/STAT3 signaling abrogates S100A7-driven breast tumorigenicity and immune suppression. Breast Cancer Res 2026;28:112.
PMID: 42057180